The proposed revised Product Liability Directive—implications for life sciences

Table of contents

• In short
• In greater detail
• What is staying the same?
• New life sciences companies and products brought within scope
• Additional criteria for assessing defect
• Introduction of rebuttable presumptions to prove defect or causation
• Extension of longstop for latent harm
• Expansion of types of compensable damage
• Representative claims permitted
• What’s next for the proposed Directive?

Article summary

Life Sciences analysis: Rachel Duffy, associate, Andrew Austin, partner, and Harriet Hanks, senior associate, at Freshfields Bruckhaus Deringer, consider the effect the proposed revised Product Liability Directive will have on the life sciences sector.